MCID: NSL022
MIFTS: 40

Nasal Cavity Disease

Categories: Respiratory diseases

Aliases & Classifications for Nasal Cavity Disease

MalaCards integrated aliases for Nasal Cavity Disease:

Name: Nasal Cavity Disease 12 14
Disorder of Nasal Cavity 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2163
NCIt 47 C27102
UMLS 69 C0339820

Summaries for Nasal Cavity Disease

MalaCards based summary : Nasal Cavity Disease, also known as disorder of nasal cavity, is related to cytoplasmic body myopathy and papillary follicular thyroid adenocarcinoma. An important gene associated with Nasal Cavity Disease is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Allograft rejection and IL-17 Family Signaling Pathways. The drugs Desflurane and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and lung, and related phenotypes are Increased transferrin (TF) endocytosis and hematopoietic system

Wikipedia : 72 The nasal cavity (nasal fossa, or nasal passage) is a large air filled space above and behind the nose... more...

Related Diseases for Nasal Cavity Disease

Diseases related to Nasal Cavity Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
id Related Disease Score Top Affiliating Genes
1 cytoplasmic body myopathy 10.8 IL13 IL5
2 papillary follicular thyroid adenocarcinoma 10.8 IL5 RNASE3
3 aortic arch interruption 10.7 IL13 IL5
4 x-linked intellectual disability, van esch type 10.7 IL4 IL5 RNASE3
5 toxic diffuse goiter 10.7 IL13 IL5 RNASE3
6 orbital plasma cell granuloma 10.7 IL4 IL5 RNASE3
7 penis agenesis 10.7 CCL11 IL5
8 myofibroma 10.7 IL13 IL5 TLR9
9 anterior dislocation of lens 10.7 CCL11 IL4 RNASE3
10 autoimmune neuropathy 10.7 IL13 IL5 RNASE3
11 central nervous system origin vertigo 10.7 IL4 MS4A2 RNASE3
12 acute necrotizing encephalopathy type 1 10.7 IL13 IL5 TLR9
13 lymphocytic gastritis 10.7 CCL11 IL5 RNASE3
14 acute ackee fruit intoxication 10.7 IL10 IL4
15 cannabis abuse 10.7 CCL11 IL5 RNASE3
16 abdominal tuberculosis 10.7 IL13 IL4 IL5
17 glucose intolerance 10.7 IL13 IL4 IL5
18 spindle cell variant squamous cell breast carcinoma 10.7 IL13 IL4 IL5
19 cholesteatoma of middle ear 10.7 CCL11 IL13 IL5
20 somatoform disorder 10.7 RNASE3 TAC1 TLR9
21 tracheomalacia 10.6 CYSLTR1 RHNO1 TRPV1
22 malignant hyperthermia 10.6 IL4 IL5 TLR9
23 eye accommodation disease 10.6 IL10 IL4
24 pseudoainhum 10.6 RNASE3 TAC1
25 cystadenocarcinoma 10.6 IL10 IL13
26 marasmus 10.6 IL4 IL5 RNASE3 TRPV1
27 atrial fibrillation 10.6 MS4A2 TRPV1
28 placenta accreta 10.6 IL4 TAC1 TRPV1
29 crustacean allergy 10.6 IL10 IL5 RNASE3
30 common peroneal nerve lesion 10.6 CXCL8 IL5
31 tularemia 10.6 IL10 IL4 TLR9
32 vascular dementia 10.6 IL10 IL4 TLR9
33 winchester syndrome 10.5 IL13 IL4 IL5 RNASE3
34 glioblastoma multiforme 10.5 IL10 IL5 RNASE3
35 purpura fulminans 10.5 IL13 IL4 IL5 RNASE3
36 ostertagiasis 10.5 IL10 IL4 TLR9
37 acute gonococcal prostatitis 10.5 IL13 IL4 IL5 RNASE3
38 motor peripheral neuropathy 10.5 IL10 IL4 TLR9
39 peroneal nerve paralysis 10.5 IL10 TLR9
40 diabetic angiopathy 10.5 IL10 IL4
41 exophthalmos 10.5 CXCL8 IL5 RNASE3
42 cow milk allergy 10.5 IL10 IL13 IL4
43 fibrosarcomatous osteosarcoma 10.5 CXCL8 TLR9 TRPV1
44 spondylolysis 10.5 CXCL8 TLR9 TRPV1
45 lagophthalmos 10.5 IL10 IL4
46 whistling face syndrome, recessive form 10.5 CXCL8 IL5 RNASE3
47 bartholin's duct cyst 10.5 CCL11 IL5 RNASE3
48 abnormal retinal correspondence 10.5 IL10 IL4 IL5
49 gastric ulcer 10.5 IL10 IL5 TLR9
50 frontal sinus schneiderian papilloma 10.5 IL13 IL5 TRPV1 TSLP

Graphical network of the top 20 diseases related to Nasal Cavity Disease:



Diseases related to Nasal Cavity Disease

Symptoms & Phenotypes for Nasal Cavity Disease

GenomeRNAi Phenotypes related to Nasal Cavity Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.4 MS4A2 PDC PDCL PTGDR2 TAC1 TLR9

MGI Mouse Phenotypes related to Nasal Cavity Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CCL11 CHD7 HRH1 IL10 IL13 IL4
2 homeostasis/metabolism MP:0005376 9.93 IL13 IL4 IL5 PDC PDCL PTGDR2
3 digestive/alimentary MP:0005381 9.87 CHD7 IL10 IL13 IL4 IL5 TLR9
4 immune system MP:0005387 9.77 IL4 IL5 MS4A2 PTGDR2 TLR9 TRPV1
5 respiratory system MP:0005388 9.23 CCL11 CHD7 CYSLTR1 IL10 IL13 IL4

Drugs & Therapeutics for Nasal Cavity Disease

Drugs for Nasal Cavity Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 618)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Desflurane Approved Phase 4 57041-67-5 42113
2
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
3
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
4
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3 2078-54-8 4943
5 Racepinephrine Approved Phase 4,Phase 3,Phase 2
6
Remifentanil Approved Phase 4 132875-61-7 60815
7
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
8
Metoprolol Approved, Investigational Phase 4,Phase 2 37350-58-6, 51384-51-1 4171
9
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
10
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2 1951-25-3 2157
11
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
12
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1 2216-51-5 16666
13
Digoxin Approved Phase 4,Phase 2,Phase 3 20830-75-5 30322 2724385
14
Montelukast Approved Phase 4 158966-92-8 5281040
15
Cefditoren Approved Phase 4 117467-28-4, 104145-95-1 9571074 9870843
16
Propafenone Approved Phase 4 54063-53-5 4932
17
Sotalol Approved Phase 4,Phase 3 959-24-0, 3930-20-9 5253
18
Ephedrine Approved Phase 4,Phase 1,Phase 2 299-42-3 9294
19
Pseudoephedrine Approved Phase 4,Phase 1,Phase 2 90-82-4 7028
20
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 137-58-6 3676
21
Oxymetazoline Approved Phase 4,Phase 2,Phase 1 1491-59-4 4636
22
Phenylephrine Approved Phase 4,Phase 2,Phase 1 59-42-7 6041
23
Ethanol Approved Phase 4,Phase 2 64-17-5 702
24
Budesonide Approved Phase 4,Phase 3,Phase 1,Phase 2 51333-22-3 63006 5281004
25
Antazoline Approved Phase 4 91-75-8 2200
26
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
27
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
28
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 26787-78-0 33613 2171
29
Dextromethorphan Approved Phase 4,Phase 1 125-71-3 5360696 5362449
30
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
31
Almotriptan Approved, Investigational Phase 4 154323-57-6, 181183-52-8 123606
32
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
33
Magnesium Sulfate Approved, Vet_approved Phase 4 7487-88-9 24083
34
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
35
Ibutilide Approved Phase 4 122647-32-9, 122647-31-8 60753
36
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
37
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
38
Cocaine Approved, Illicit Phase 4,Phase 3 50-36-2 5760 446220
39
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
40
Thrombin Approved Phase 4
41
Dofetilide Approved Phase 4 115256-11-6 71329
42
Quinidine Approved Phase 4 56-54-2 441074
43
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
44
Telithromycin Approved Phase 4 191114-48-4 5462516
45
Azithromycin Approved Phase 4,Phase 3,Phase 2 83905-01-5 55185 53477736 447043
46
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
47
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
48
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
49
Nicotine Approved Phase 4 54-11-5 942 89594
50
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474

Interventional clinical trials:

(show top 50) (show all 949)

id Name Status NCT ID Phase Drugs
1 Comparision Between Hemodynamic Response of Dexmedetomidine and Remifentanil on Anesthesia in Endoscopic Sinus Surgery Unknown status NCT02464722 Phase 4 Dexmedetomidine;Remifentanil;Epinephrine;Propofol;Rocuronium
2 Remifentanil and Controlled Hypotension for Functional Endoscopic Sinus Surgery: Comparison With Tramadol and Metoprolol Unknown status NCT02484859 Phase 4 Remifentanil;Tramadol;Metoprolol
3 Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias Unknown status NCT01717469 Phase 4
4 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
5 Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Using Ultrasound Activated Pins Unknown status NCT02449707 Phase 4
6 Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
7 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
8 Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery Unknown status NCT02110654 Phase 4 Montelukast;mometasone furoate nasal spray
9 Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions Unknown status NCT01750775 Phase 4 Shensong Yangxin capsule;placebo Capsule
10 Vernakalant Versus Flecainide: Atrial Contractility Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
11 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
12 Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
13 Study of Cefditoren Pivoxil in Treatment of Childhood With Acute Rhinosinusitis Unknown status NCT01553006 Phase 4 cefditoren pivoxil
14 Efficacy of a Pacemaker Algorithm in Promotion of the Intrinsic Heart Activity. Unknown status NCT00156741 Phase 4
15 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
16 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
17 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
18 Falls and Cardiovascular Events in Pacemaker Patients Completed NCT01037426 Phase 4
19 Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease Completed NCT01170611 Phase 4
20 Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation Completed NCT00845780 Phase 4 withdrawal or continuation of amiodarone therapy
21 Spontaneous Atrio Ventricular Conduction Preservation Completed NCT00655213 Phase 4
22 Beluga - Clinical Observations of Automatic Algorithms for Cardiac Pacing Completed NCT00286858 Phase 4
23 Comparison Between 2 Bilateral Internal Thoracic Artery Coronary Artery Bypass Grafting Configurations Completed NCT01666366 Phase 4
24 The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device Completed NCT02079792 Phase 4
25 DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients. Completed NCT00478933 Phase 4
26 Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation Completed NCT01527279 Phase 4 antazoline;0.9% saline
27 Proteomic Profiling for Influenza Completed NCT00133588 Phase 4
28 Treatment of Acute Sinusitis Completed NCT00377403 Phase 4 Acetaminophen;Amoxicillin;Dextromethorphan hydrobromide with guaifenesin;Guaifenesin;Pseudoephedrine Sustained Action;Saline spray (0.65%)
29 Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers Completed NCT00208065 Phase 4 almotriptan or pseudoephedrine
30 Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis Completed NCT00396162 Phase 4 probiotic containing L.rhamnosus R0011 strain
31 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit Completed NCT01461733 Phase 4 amiodarone;Placebo
32 The Human Mucosal Immune Responses to Influenza Virus (SLVP026) Completed NCT03023553 Phase 4
33 The Effect of Packing in Post Operative Management of FESS Completed NCT00793117 Phase 4
34 Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia Completed NCT00232232 Phase 4 Fish oil
35 Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD Completed NCT02576626 Phase 4 indacaterol/glycopyrronium 110/50 Breezhaler®;ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation
36 Controlled Hypotension During Functional Endoscopic Sinus Surgery Completed NCT01956981 Phase 4 Magnesium Sulfate;Dexmedetomidine
37 The Infected Bone Nonunion and Soft Tissue Defect of Long Bone Treated Simultaneously With Ilizarov Technique Completed NCT00846261 Phase 4
38 Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel Completed NCT00554190 Phase 4
39 The PIO II Study of In-office Placement of a Steroid-eluting Sinus Implant Completed NCT02668302 Phase 4
40 Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Completed NCT01447862 Phase 4 Brinavess (Vernakalant);Corvert (Ibutilide)
41 Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess Completed NCT01537783 Phase 4 Chlorhexidine gluconate;Mupirocin
42 Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery Completed NCT01706952 Phase 4 Cocaine;Adrenaline
43 Hemostatic Matrix in Endoscopic Sinus Surgery Completed NCT00242437 Phase 4
44 The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine Completed NCT02477293 Phase 4 Hyeonggaeyeongyo-tang
45 Saline Irrigation After Surgery in Patients With Chronic Sinusitis Completed NCT01575223 Phase 4
46 Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial Completed NCT00256152 Phase 4
47 Clinical Evaluation on Advanced Resynchronization Completed NCT00658203 Phase 4
48 The Influence of Dimensional Anatomic Variables on the Outcomes of Maxillary Sinus Grafting Procedures Completed NCT00868777 Phase 4
49 A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation Completed NCT00540787 Phase 4 Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs
50 Medicated Punctured-Glove-Finger Spacer Study Completed NCT01420471 Phase 4 Triamcinolone

Search NIH Clinical Center for Nasal Cavity Disease

Genetic Tests for Nasal Cavity Disease

Anatomical Context for Nasal Cavity Disease

MalaCards organs/tissues related to Nasal Cavity Disease:

39
Heart, Bone, Lung, Brain, Colon, Kidney, Bone Marrow

Publications for Nasal Cavity Disease

Variations for Nasal Cavity Disease

Expression for Nasal Cavity Disease

Search GEO for disease gene expression data for Nasal Cavity Disease.

Pathways for Nasal Cavity Disease

Pathways related to Nasal Cavity Disease according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.6 CCL11 CXCL8 IL10 IL13 IL4 IL5
2
Show member pathways
12.3 CCL11 CXCL8 IL13 IL4 IL5
3
Show member pathways
12.18 IL10 IL13 IL4 IL5 TSLP
4
Show member pathways
12.12 CCL11 CXCL8 IL4 TLR9
5 12.1 CXCL8 IL10 IL13 TAC1
6
Show member pathways
12.08 CXCL8 IL10 IL13 IL4 IL5
7 11.95 IL10 IL4 IL5 PTGDR2
8 11.91 CCL11 CXCL8 IL10 IL13 IL4
9 11.77 CXCL8 IL13 IL4 IL5
10 11.68 IL10 IL4 IL5 TLR9
11
Show member pathways
11.66 CXCL8 IL4 IL5
12 11.62 CCL11 IL10 IL4 IL5
13 11.49 CXCL8 IL10 IL13 IL4
14 11.45 CXCL8 IL10 TLR9
15 11.35 CCL11 CXCL8 IL13 IL4 IL5
16 11.24 IL13 IL4 IL5 TSLP
17 11.18 IL10 IL13 IL4 IL5
18 11.08 CCL11 CXCL8 IL10 IL13 IL4 IL5
19 11.04 IL10 IL13 IL4 IL5
20 11.03 CCL11 IL10 IL13 IL4 IL5
21 11 IL10 IL13 IL4 IL5 PTGDR2 TSLP
22 10.86 IL13 IL4 IL5

GO Terms for Nasal Cavity Disease

Cellular components related to Nasal Cavity Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CCL11 CXCL8 IL10 IL13 IL4 IL5
2 external side of plasma membrane GO:0009897 9.46 IL13 IL4 MS4A2 TRPV1
3 extracellular space GO:0005615 9.32 CCL11 CXCL8 IL10 IL13 IL4 IL5

Biological processes related to Nasal Cavity Disease according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.77 CCL11 CXCL8 CYSLTR1 IL4 PTGDR2
2 neuropeptide signaling pathway GO:0007218 9.73 CYSLTR1 NPS PTGDR2 TAC1
3 negative regulation of endothelial cell apoptotic process GO:2000352 9.63 IL10 IL13 IL4
4 positive regulation of macrophage activation GO:0043032 9.61 IL10 IL13
5 positive regulation of synaptic transmission, GABAergic GO:0032230 9.6 NPS TAC1
6 positive regulation of mast cell degranulation GO:0043306 9.59 IL13 IL4
7 eosinophil chemotaxis GO:0048245 9.58 CCL11 HRH1
8 positive regulation of MHC class II biosynthetic process GO:0045348 9.58 IL10 IL4
9 microglial cell activation GO:0001774 9.58 IL13 IL4 TRPV1
10 positive regulation of action potential GO:0045760 9.56 NPS TAC1
11 immune response GO:0006955 9.56 CCL11 CXCL8 IL10 IL13 IL4 IL5
12 type 2 immune response GO:0042092 9.55 IL10 IL4
13 negative regulation of interleukin-8 production GO:0032717 9.54 IL10 TLR9
14 queuosine biosynthetic process GO:0008616 9.52 PDC PDCL
15 regulation of isotype switching GO:0045191 9.51 IL10 IL4
16 response to molecule of bacterial origin GO:0002237 9.5 CXCL8 IL10 TLR9
17 regulation of proton transport GO:0010155 9.49 IL13 IL4
18 negative regulation of complement-dependent cytotoxicity GO:1903660 9.48 IL13 IL4
19 positive regulation of B cell proliferation GO:0030890 9.33 IL13 IL4 IL5
20 inflammatory response GO:0006954 9.32 CCL11 CXCL8 HRH1 IL10 IL13 IL5
21 positive regulation of immunoglobulin production GO:0002639 9.26 IL13 IL4
22 signal transduction GO:0007165 10.22 CCL11 CXCL8 CYSLTR1 HRH1 IL13 MS4A2

Molecular functions related to Nasal Cavity Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL11 CXCL8 IL10 IL13 IL4 IL5
2 queuine tRNA-ribosyltransferase activity GO:0008479 8.96 PDC PDCL

Sources for Nasal Cavity Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....